Cystitis Clinical Trial
Official title:
Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study
The goal of this clinical research study is to learn how the body absorbs and processes 1
dose of cidofovir that is given directly into the bladder, in patients with a viral infection
that is causing bleeding from the bladder.
The safety of this drug dose and the investigational way it is given (directly into the
bladder) will also be studied.
The Study Drug:
Cidofovir is designed to fight CMV (a viral infection) by blocking the CMV cells from
dividing.
Cidofovir is commonly given by injection. For research purposes, in this study it will be
given directly into the bladder through a foley catheter. This is one of the first studies
where cidofovir is being given this way in humans.
Study Drug Administration:
If you are found to be eligible to take part in this study, on Day 1, Cidofovir will be put
into your bladder through your foley catheter. The catheter will be clamped for 2 hours to
keep the drug in your bladder. After 2 hours, the catheter will be unclamped. If you were
receiving bladder irrigation as therapy for your hemorrhagic cystitis, this will be
restarted.
Study Tests on Day 1:
On the day you receive cidofovir, blood (about 2 teaspoons) will be drawn 6 times. The first
blood draw will occur before the cidofovir dose, and the last blood draw will occur 24 hours
(+/- 1 hour) after the start of the dose. This blood will be used for pharmacokinetic (PK)
and pharmacodynamic (PD) testing. PK testing measures the amount of study drug in the body at
different time points. PD testing is used to look at how the level of study drug in your body
may affect the disease.
Viral Load Testing:
During this study, extra urine and leftover blood to be collected and used for research to
test for certain viruses. These viruses include the type of infection you had when joining
this study, as well as cytomegalovirus (CMV) and another type of herpes virus.
The urine samples will be collected before the cidofovir dose on Day 1, after the cidofovir
dose on Day 1, and again on Day 4.
Any blood left over from Day 1 testing will also be used for viral load testing.
It is possible that these urine and/or blood samples will be sent to an outside lab to
perform this testing. If that occurs, your name and any personal identifying information will
be coded before the samples are sent. Coding the samples is designed to protect your privacy.
Follow-Up Tests:
Blood (about 2 teaspoons) will be drawn for routine tests 2 times during the week after your
cidofovir dose.
On Day 7 (+/- 2 days), you will be checked for any side effects that could be related to the
study drug.
In addition, on Day 14 (+/- 2 days), blood samples will be drawn for PK testing, urine will
be collected for routine tests, and your safety data will be recorded.
One final follow-up visit will take place on Day 30 (+/- 2 days). During this visit, the
study staff will record any serious side effects you may be experiencing.
Length of Study Participation:
Your active study participation will be over after the Day 7 follow-up visit (+/- 2 days). If
you experienced a side effect, however, the study staff will continue checking your medical
records until the side effect becomes stable or gets better.
This is an investigational study. Cidofovir given by injection is commercially available and
FDA approved to treat CMV in patients with HIV. It is investigational to give cidofovir
directly into the bladder of patients who have a viral infection causing bleeding in the
bladder.
Up to 6 patients will take part in this study. All will be enrolled at M. D. Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00361998 -
Nitrofurantoin Macrocrystals 3 Days Versus 7 Days in the Treatment of Women With Uncomplicated Cystitis
|
Phase 4 | |
| Completed |
NCT03275623 -
Management of Sub-Clinical Bacteriuria in Pregnancy
|
Phase 4 | |
| Not yet recruiting |
NCT05055544 -
Bearberry in the Treatment of Cystitis
|
N/A | |
| Active, not recruiting |
NCT01966653 -
Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women
|
Phase 4 | |
| Withdrawn |
NCT01527019 -
Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)
|
Phase 3 | |
| Completed |
NCT03877289 -
Efficacy of Oxybutynin in Paediatric Cystitis
|
Phase 4 | |
| Completed |
NCT05584657 -
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
|
Phase 3 | |
| Terminated |
NCT00164099 -
The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study
|
Phase 4 | |
| Completed |
NCT00528476 -
Risk Factors for Recurrent Urinary Tract Infection in Children
|
N/A | |
| Completed |
NCT04987164 -
Incidence of Cystitis in Women Consuming a Mixture of Cranberry, Cinnamon, Probiotics
|
||
| Completed |
NCT01861353 -
Cranberry-lingonberry Juice Started During Acute Infection in Prevention of Urinary Tract Infections in Children
|
N/A | |
| Completed |
NCT00957333 -
Effects of Ketamine on Human Bladders and Its Possible Mechanisms
|
N/A | |
| Completed |
NCT05945667 -
Efficacy and Safety of Uronext® in Women With Cystitis
|
N/A | |
| Recruiting |
NCT05360914 -
Hospital at Home for Elderly Acute Ill Patients
|
N/A | |
| Completed |
NCT04272281 -
Use of a Share Decision Making Tool in the Care of Acute Cystitis Without Risk of Complication in Primary Care
|
N/A | |
| Completed |
NCT03425396 -
Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis
|
Phase 2 | |
| Completed |
NCT05260554 -
Effect of Cranberry Extract on the Urinary System
|
||
| Unknown status |
NCT00622076 -
Postoperative Catheterization After Anterior Colporrhaphy
|
N/A | |
| Completed |
NCT00801021 -
Treatment and/or Prevention of Urinary Tract Infections
|
Phase 1 | |
| Terminated |
NCT01060254 -
A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain
|
Phase 2 |